SEARCH

SEARCH BY CITATION

References

  • Agura, E., Niesvizky, R., Matous, J., Munshi, N., Hussein, M., Parameswaran, R.V., Tarantolo, S., Whiting, N.C., Drachman, J.G. & Zonder, J.A. (2009) Dacetuzumab (SGN-40), lenalidomide, and weekly dexamethasone in relapsed or refractory multiple myeloma: multiple responses observed in a phase 1b study. Blood (ASH Annual Meeting Abstracts), 114, Abstract 2870.
  • Burton, J.D., Ely, S., Reddy, P.K., Stein, R., Gold, D.V., Cardillo, T.M. & Goldenberg, D.M. (2004) CD74 is expressed by multiple myeloma and is a promising target for therapy. Clinical Cancer Research, 10, 66066611.
  • Callander, N.S., Markovina, S., Juckett, M.B., Wagner, E., Kolesar, J., Longo, W., Williams, E.C., Kim, K., Werndli, J. & Miyamoto, S. (2009) The addition of bevacizumab (B) to lenalidomide and low dose dexamethasone does not significantly increase response in relapsed or refractory multiple myeloma (NCI#7317). Blood (ASH Annual Meeting Abstracts), 114, Abstract 3885.
  • Campbell, K.S. & Purdy, A.K. (2011) Structure/function of human killer cell immunoglobulin-like receptors: lessons from polymorphisms, evolution, crystal structures and mutations. Immunology, 132, 315325.
  • Di Bernardo, A., Macor, P., Guarnotta, C., Franco, G., Florena, A.M., Tedesco, F. & Tripodo, C. (2010) Humoral immunotherapy of multiple myeloma: perspectives and perplexities. Expert Opinion on Biological Therapy, 10, 863873.
  • Fulciniti, M., Hideshima, T., Vermot-Desroches, C., Pozzi, S., Nanjappa, P., Shen, Z., Patel, N., Smith, E.S., Wang, W., Prabhala, R., Tai, Y.T., Tassone, P., Anderson, K.C. & Munshi, N.C. (2009a) A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. Clinical Cancer Research, 15, 71447152.
  • Fulciniti, M., Tassone, P., Hideshima, T., Vallet, S., Nanjappa, P., Ettenberg, S.A., Shen, Z., Patel, N., Tai, Y.T., Chauhan, D., Mitsiades, C., Prabhala, R., Raje, N., Anderson, K.C., Stover, D.R. & Munshi, N.C. (2009b) Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood, 114, 371379.
  • Hayashi, T., Treon, S.P., Hideshima, T., Tai, Y.T., Akiyama, M., Richardson, P., Chauhan, D., Grewal, I.S. & Anderson, K.C. (2003) Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells. British Journal of Haematology, 121, 592596.
  • Heath, D.J., Chantry, A.D., Buckle, C.H., Coulton, L., Shaughnessy, Jr, J.D., Evans, H.R., Snowden, J.A., Stover, D.R., Vanderkerken, K. & Croucher, P.I. (2009) Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. Journal of Bone and Mineral Research, 24, 425436.
  • Hsi, E.D., Steinle, R., Balasa, B., Szmania, S., Draksharapu, A., Shum, B.P., Huseni, M., Powers, D., Nanisetti, A., Zhang, Y., Rice, A.G., van Abbema, A., Wong, M., Liu, G., Zhan, F., Dillon, M., Chen, S., Rhodes, S., Fuh, F., Tsurushita, N., Kumar, S., Vexler, V., Shaughnessy, Jr, J.D., Barlogie, B., van Rhee, F., Hussein, M., Afar, D.E.H. & Williams, M.B. (2008) CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clinical Cancer Research, 14, 27752784.
  • Ikeda, H., Hideshima, T., Fulciniti, M., Lutz, R.J., Yasui, H., Okawa, Y., Kiziltepe, T., Vallet, S., Pozzi, S., Santo, L., Perrone, G., Tai, Y.T., Cirstea, D., Raje, N.S., Uherek, C., Dalken, B., Aigner, S., Osterroth, F., Munshi, N., Richardson, P. & Anderson, K.C. (2009) The monoclonal antibody nBT062 conjugated to cytotoxic maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clinical Cancer Research, 15, 40284037.
  • Ishii, T., Chanan-Khan, A., Jafferjee, J., Ersing, N., Takahashi, H., Mizutani, M., Shiotsu, Y. & Hanai, N. (2008) A humanized anti-ganglioside GM2 antibody, BIW-8962, exhibits ADCC/CDC activity against multiple myeloma cells and potent anti-tumor activity in mouse xenograft models. Blood (ASH Annual Meeting Abstracts), 112, Abstract 1718.
  • Jagannath, S., Kyle, R.A., Palumbo, A., Siegel, D.S., Cunningham, S. & Berenson, J. (2010) The current status and future of multiple myeloma in the clinic. Clinical Lymphoma, Myeloma and Leukemia, 10, 2843.
  • Jakubowiak, A.J., Benson, Jr, D.M., Bensinger, W., Siegel, D.S., Zimmerman, T., Mohrbacher, A., Richardson, P., Afar, D.E.H., Singhal, A.K. & Anderson, K.C. (2010) Elotuzumab in combination with bortezomib in patients with relapsed/refractory multiple myeloma: updated results of a phase 1 study. Blood (ASH Annual Meeting Abstracts), 116, Abstract 3023.
  • Jemal, A., Siegel, R., Xu, J. & Ward, E. (2010) Cancer statistics, 2010. CA: A Cancer Journal for Clinicians, 60, 277300.
  • Kapoor, P., Greipp, P.T., Morice, W.G., Rajkumar, S.V., Witzig, T.E. & Greipp, P.R. (2008) Anti-CD20 monoclonal antibody therapy in multiple myeloma. British Journal of Haematology, 141, 135148.
  • Kastritis, E., Charidimou, A., Varkaris, A. & Dimopoulos, M.A. (2009) Targeted therapies in multiple myeloma. Targeted Oncology, 4, 2336.
  • Kristinsson, S.Y., Landgren, O., Dickman, P.W., Derolf, A.R. & Bjorkholm, M. (2007) Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. Journal of Clinical Oncology, 25, 19931999.
  • Kumar, S.K., Rajkumar, S.V., Dispenzieri, A., Lacy, M.Q., Hayman, S.R., Buadi, F.K., Zeldenrust, S.R., Dingli, D., Russell, S.J., Lust, J.A., Greipp, P.R., Kyle, R.A. & Gertz, M.A. (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood, 111, 25162520.
  • Lonial, S., Vij, R., Harousseau, J.-L., Facon, T., Moreau, P., Leleu, X., Mazumder, A., Kaufman, J.L., Westland, C.E., Tsao, C., Singhal, A.K. & Jagannath, S. (2010) Elotuzumab in combination with lenalidomide and low-dose dexamethasone in patients with relasped/refractory multiple myeloma: results of a phase 1 study. Blood (ASH Annual Meeting Abstracts), 116, Abstract 1936.
  • Lutz, R.J. & Whiteman, K.R. (2009) Antibody-maytansinoid conjugates for the treatment of myeloma. Monoclonal Antibodies, 1, 548551.
  • Mechtersheimer, G., Staudter, M. & Möller, P. (1992) Expression of the natural killer (NK) cell-associated antigen CD56 (Leu-19), which is identical to the 140-kDa isoform of N-CAM, in neural and skeletal muscle cells and tumors derived therefrom. Annals of the New York Academy of Sciences, 650, 311316.
  • Mhaskar, R., Redzepovic, J., Wheatley, K., Clark, O.A., Miladinovic, B., Glasmacher, A., Kumar, A. & Djulbegovic, B. (2010) Bisphosphonates in multiple myeloma. The Cochrane Database of Systematic Reviews, Issue 3. Art. No.: CD003188.
  • Moreau, P., Harousseau, J.-L., Wijdenes, J., Morineau, N., Milpied, N. & Bataille, R. (2000) A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response rates in advanced multiple myeloma. British Journal of Haematology, 109, 661664.
  • Moreau, P., Hullin, C., Garban, F., Yakoub-Agha, I., Benboubker, L., Attal, M., Marit, G., Fuzibet, J.-G., Doyen, C., Voillat, L., Berthou, C., Ketterer, N., Casassus, P., Monconduit, M., Michallet, M., Najman, A., Sotto, J.-J., Bataille, R., Harousseau, J.-L. & for the Intergroupe Francophone du Myelome group (2006) Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol. Blood, 107, 397403.
  • Moreaux, J., Hose, D., Reme, T., Jourdan, E., Hundemer, M., Legouffe, E., Moine, P., Bourin, P., Moos, M., Corre, J., Mohler, T., De Vos, J., Rossi, J.F., Goldschmidt, H. & Klein, B. (2006) CD200 is a new prognostic factor in multiple myeloma. Blood, 108, 41944197.
  • Niesvizky, R., Ely, S., Mark, T., Aggarwal, S., Gabrilove, J.L., Wright, J.J., Chen-Kiang, S. & Sparano, J.A. (2011) Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer, 117, 336342.
  • Raschko, M., Markovina, S., Miyamoto, S., Longo, W., Williams, E., McFarland, T., Werndli, J., Wagner, E., Juckett, M. & Callander, N. (2007) Phase II trial of bevacizumab combined with low dose dexamethasone and lenalidomide (BEV/REV/DEX) for relapsed or refractory myeloma (MM). Blood (ASH Annual Meeting Abstracts), 110, Abstract 1173.
  • van Rhee, F., Szmania, S.M., Dillon, M., van Abbema, A.M., Li, X., Stone, M.K., Garg, T.K., Shi, J., Moreno-Bost, A.M., Yun, R., Balasa, B., Ganguly, B., Chao, D., Rice, A.G., Zhan, F., Shaughnessy, Jr, J.D., Barlogie, B., Yaccoby, S. & Afar, D.E.H. (2009) Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Molecular Cancer Therapeutics, 8, 26162624.
  • van Rhee, F., Fayad, L., Voorhees, P., Furman, R., Lonial, S., Borghaei, H., Sokol, L., Crawford, J., Cornfeld, M., Qi, M., Qin, X., Herring, J., Casper, C. & Kurzrock, R. (2010) Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman’s disease. Journal of Clinical Oncology, 28, 37013708.
  • Richardson, P.G., Mitsiades, C., Schlossman, R., Munshi, N. & Anderson, K. (2007) New drugs for myeloma. Oncologist, 12, 664689.
  • Richardson, P.G., Moreau, P., Jakubowiak, A.J., Facon, T., Jagannath, S., Vij, R., Reece, D.E., White, D.J., Raab, M.S., Benboubker, L., Rossi, J.-F., Tsao, C., Fry, J., Berman, D., Singhal, A.K. & Lonial, S. (2010) Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: interim results of a phase 2 study. Blood (ASH Annual Meeting Abstracts), 116, Abstract 986.
  • Robillard, N., Avet-Loiseau, H., Garand, R., Moreau, P., Pineau, D., Rapp, M.-J., Harousseau, J.-L. & Bataille, R. (2003) CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma. Blood, 102, 10701071.
  • Rosenblatt, J., Vasir, B., Uhl, L., Blotta, S., MacNamara, C., Somaiya, P., Wu, Z., Joyce, R., Levine, J.D., Dombagoda, D., Yuan, Y.E., Francoeur, K., Fitzgerald, D., Richardson, P., Weller, E., Anderson, K., Kufe, D., Munshi, N. & Avigan, D. (2011) Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Blood, 117, 393402.
  • Rossi, J.-F., Manges, R.F., Sutherland, H.J., Jagannath, S., Voorhees, P., Sonneveld, P., Delforge, M., Pegourie, B., Alegre, A., de la Rubia, J., La Police, D., Bandekar, R., Xie, H. & Orlowski, R.Z. (2008) Preliminary Results of CNTO 328, An Anti-Interleukin-6 Monoclonal Antibody, in Combination with Bortezomib in the Treatment of Relapsed or Refractory Multiple Myeloma. Blood (ASH Annual Meeting Abstracts), 112, Abstract 867.
  • Rothenberg, M.L., Carbone, D.P. & Johnson, D.H. (2003) Improving the evaluation of new cancer treatments: challenges and opportunities. Nature Reviews Cancer, 3, 303309.
  • Salles, G., Seymour, J.F., Offner, F., Lopez-Guillermo, A., Belada, D., Xerri, L., Feugier, P., Bouabdallah, R., Catalano, J.V., Brice, P., Caballero, D., Haioun, C., Pedersen, L.M., Delmer, A., Simpson, D., Leppa, S., Soubeyran, P., Hagenbeek, A., Casasnovas, O., Intragumtornchai, T., Ferme, C., da Silva, M.G., Sebban, C., Lister, A., Estell, J.A., Milone, G., Sonet, A., Mendila, M., Coiffier, B. & Tilly, H. (2011) Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet, 377, 4251.
  • San Miguel, J.F., Schlag, R., Khuageva, N.K., Dimopoulos, M.A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M.T., Palumbo, A., Samoilova, O.S., Dmoszynska, A., Abdulkadyrov, K.M., Schots, R., Jiang, B., Mateos, M.V., Anderson, K.C., Esseltine, D.L., Liu, K., Cakana, A., van de Velde, H. & Richardson, P.G. (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. New England Journal of Medicine, 359, 906917.
  • Sapra, P., Stein, R., Pickett, J., Qu, Z., Govindan, S.V., Cardillo, T.M., Hansen, H.J., Horak, I.D., Griffiths, G.L. & Goldenberg, D.M. (2005) Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys. Clinical Cancer Research, 11, 52575264.
  • Shah, J.J., Zonder, J.A., Cohen, A., Weber, D., Thomas, S., Wang, M., Kaufman, J.L., Burt, S.M., Walker, D., Freeman, B., Rush, S.A., Ptaszynski, A., Orlowski, R.Z. & Lonial, S. (2010) A phase I/II trial of the KSP inhibitor ARRY-520 in relapsed/refractory multiple myeloma. Blood (ASH Annual Meeting Abstracts), 116, Abstract 1959.
  • Stevenson, G.T. (2006) CD38 as a therapeutic target. Molecular Medicine, 12, 345346.
  • Tai, Y.T., Podar, K., Gupta, D., Lin, B., Young, G., Akiyama, M. & Anderson, K.C. (2002) CD40 activation induces p53-dependent vascular endothelial growth factor secretion in human multiple myeloma cells. Blood, 99, 14191427.
  • Tai, Y.T., Podar, K., Mitsiades, N., Lin, B., Mitsiades, C., Gupta, D., Akiyama, M., Catley, L., Hideshima, T., Munshi, N.C., Treon, S.P. & Anderson, K.C. (2003) CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling. Blood, 101, 27622769.
  • Tai, Y.T., Catley, L.P., Mitsiades, C.S., Burger, R., Podar, K., Shringpaure, R., Hideshima, T., Chauhan, D., Hamasaki, M., Ishitsuka, K., Richardson, P., Treon, S.P., Munshi, N.C. & Anderson, K.C. (2004) Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. Cancer Research, 64, 28462852.
  • Tai, Y.T., Li, X.F., Catley, L., Coffey, R., Breitkreutz, I., Bae, J., Song, W., Podar, K., Hideshima, T., Chauhan, D., Schlossman, R., Richardson, P., Treon, S.P., Grewal, I.S., Munshi, N.C. & Anderson, K.C. (2005a) Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40–induced cytotoxicity in human multiple myeloma: clinical implications. Cancer Research, 65, 1171211720.
  • Tai, Y.T., Li, X., Tong, X., Santos, D., Otsuki, T., Catley, L., Tournilhac, O., Podar, K., Hideshima, T., Schlossman, R., Richardson, P., Munshi, N.C., Luqman, M. & Anderson, K.C. (2005b) Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. Cancer Research, 65, 58985906.
  • Tai, Y.T., Dillon, M., Song, W., Leiba, M., Li, X.F., Burger, P., Lee, A.I., Podar, K., Hideshima, T., Rice, A.G., van Abbema, A., Jesaitis, L., Caras, I., Law, D., Weller, E., Xie, W., Richardson, P., Munshi, N.C., Mathiot, C., Avet-Loiseau, H., Afar, D.E. & Anderson, K.C. (2008) Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood, 112, 13291337.
  • Tassone, P., Gozzini, A., Goldmacher, V., Shammas, M.A., Whiteman, K.R., Carrasco, D.R., Li, C., Allam, C.K., Venuta, S., Anderson, K.C. & Munshi, N.C. (2004a) In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2’-deacetyl-N2’-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells. Cancer Research, 64, 46294636.
  • Tassone, P., Goldmacher, V.S., Neri, P., Gozzini, A., Shammas, M.A., Whiteman, K.R., Hylander-Gans, L.L., Carrasco, D.R., Hideshima, T., Shringarpure, R., Shi, J., Allam, C.K., Wijdenes, J., Venuta, S., Munshi, N.C. & Anderson, K.C. (2004b) Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. Blood, 104, 36883696.
  • Trikha, M., Corringham, R., Klein, B. & Rossi, J.F. (2003) Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clinical Cancer Research, 9, 46534665.
  • Veikkola, T., Karkkainen, M., Claesson-Welsh, L. & Alitalo, K. (2000) Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Research, 60, 203212.
  • Vij, R., Horvath, N., Spencer, A., Taylor, K., Vadhan-Raj, S., Vescio, R., Smith, J., Qian, Y., Yeh, H. & Jun, S. (2009) An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma. American Journal of Hematology, 84, 650656.
  • Voorhees, P.M., Chen, Q., Small, G.W., Kuhn, D.J., Hunsucker, S.A., Nemeth, J.A. & Orlowski, R.Z. (2009) Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death. British Journal of Haematology, 145, 481490.
  • Weber, D.M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E.A., Siegel, D., Borrello, I., Rajkumar, S.V., Chanan-Khan, A.A., Lonial, S., Yu, Z., Patin, J., Olesnyckyj, M., Zeldis, J.B. & Knight, R.D. (2007) Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. New England Journal of Medicine, 357, 21332142.
  • Weiner, L.M., Surana, R. & Wang, S. (2010) Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nature Reviews Immunology, 10, 317327.
  • Yoshio-Hoshino, N., Adachi, Y., Aoki, C., Pereboev, A., Curiel, D.T. & Nishimoto, N. (2007) Establishment of a new interleukin-6 (IL-6) receptor inhibitor applicable to the gene therapy for IL-6–dependent tumor. Cancer Research, 67, 871875.
  • Zonder, J.A., Singhal, S., Bensinger, W., Mohrbacher, A., Hussein, M.A., Munshi, N.C., Caras, I., Singhal, A. & van Rhee, F. (2008) Phase I study of elotuzumab (HuLuc63) in relapsed/refractory multiple myeloma. Blood (ASH Annual Meeting Abstracts), 112, Abstract 2773.